Molecular Docking Evaluation of Cedrus deodara Secondary Metabolites as a Potent Anti-ovarian Cancer Agent

Year : 2023 | Volume : 01 | Issue : 01 | Page : 77 93
    By

    Priyadharshini Pillai,

  1. Student, Department of Biotechnology, Pillai College of Arts, Commerce and Science (Autonomous), New Panvel, Mumbai, Maharashtra, India

Abstract

Objective: According to the statistics for the year 2022 it was seen that cancer total cases is 14,61,427. After breast cancer, ovarian cancer is the second most frequent cancer among women. The estrogen receptor (PDB ID: 1X7E), progesterone receptor (PDB ID: 1A28), and Phosphoinositide 3-kinases (PDB ID: 4FJY) can be considered as target protein for ovarian cancer. The plant Cedrus deodara and its phytochemicals were chosen in this study to identify their pharmacological characteristics and the inhibitory effects against the target protein which is said to be involved in ovarian cancer. Infugem and Melphalan are FDA-approved ovarian cancer drugs. This drug is also chosen to compare the inhibitory effect of plant derivatives and the drugs. Methods: In this study, 30 phytochemicals were selected to know their binding affinity towards the protein targets.2 FDA-approved were also docked against all three target proteins. The target proteins were purified, and the missing residue was modeled using BIOVIA Discovery Studio then the protein structure analysis was also performed using PDBsum Generate. Using ADMETlab 2.0 pharmacological studies were performed. Result: The Oleanolic acid and 7beta-Hydroxydehydroabietic acid ligands showed the lowest binding affinity towards all three target proteins. By comparing the docking results of phytochemicals and FDA-approved drugs it is seen that the plant phytochemicals have the best binding affinity, and all the phytochemicals fulfill the criteria of ADMET analysis. Conclusion: According to the result observed from docking we can conclude that the ligands Oleanolic acid and 7beta-Hydroxydehydroabietic acid are showing inhibitory action against all three target proteins. Further In vitro study must be performed

Keywords: Molecular docking, ovarian cancer, progesterone receptor, phosphoinositide 3-kinases, Cedrus deodara, ADMET analysis

[This article belongs to International Journal of Molecular Biotechnological Research ]

How to cite this article:
Priyadharshini Pillai. Molecular Docking Evaluation of Cedrus deodara Secondary Metabolites as a Potent Anti-ovarian Cancer Agent. International Journal of Molecular Biotechnological Research. 2023; 01(01):77-93.
How to cite this URL:
Priyadharshini Pillai. Molecular Docking Evaluation of Cedrus deodara Secondary Metabolites as a Potent Anti-ovarian Cancer Agent. International Journal of Molecular Biotechnological Research. 2023; 01(01):77-93. Available from: https://journals.stmjournals.com/ijmbr/article=2023/view=106817


Browse Figures

References

1. Qazi S, Raza K. Phytochemicals from Ayurvedic plants as potential medicaments for ovarian cancer: an in silico analysis. J Mol Model. 2021;27(4):114. doi: 10.1007/s00894–021–04736-x.
2. Kooti W, Servatyari K, Behzadifar M, Asadi-Samani M, Sadeghi F, Nouri B et al. Effective medicinal plant in cancer treatment, part 2: Review study. J Evid Based Complementary Altern Med. 2017;22(4):982–95. doi: 10.1177/2156587217696927.
3. Puri S, Chadha V, Pandey AK. Epidemiology of ovarian tumours in Northern India – A tertiary hospital based study. Indian J Community Fam Med. 2018;4(2):37. doi: 10.4103/2395–2113.251437.
4. Akinleye A, Avvaru P, Furqan M, Song Y, Liu D. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol. 2013;6(1):88. doi: 10.1186/1756–8722–6–88.
5. Ng CW, Wong KK. Impact of estrogen receptor expression on prognosis of ovarian cancer according to antibody clone used for immunohistochemistry: a meta-analysis. J Ovarian Res. 2022;15(1):63. doi: 10.1186/s13048–022–01001–4.
6. Raedler LA. Infugem (gemcitabine) first formulation of premixed, ready-to-administer intravenous chemotherapy approved for several tumor types. Fourth Annual Oncology Guide to New FDA Approvals. Spring 2019;Special Feature: 25–27.
7. Gupta S, Walia A, Malan R. Phytochemistry and pharmacology of Cedrus deodera: an overview. Int J Pharm Sci Res. 2011;2(8), 2010.
8. Jain SK. Dictionary of Indian Folk Medicine and Ethnobotany: A Reference Manual of Man-Plant Relationships Ethnic Groups & Ethnobotanists in India. New Delhi: Deep Publications; 1991.
9. Shafabakhsh R, Asemi Z. Quercetin: a natural compound for ovarian cancer treatment. J Ovarian Res. 2019;12(1):55. doi: 10.1186/s13048–019–0530–4.
10. Mukherjee PK. Exploring botanicals in Indian system of medicine—regulatory perspectives. Clin Res Regul Aff. 2003;20(3):249–64. doi: 10.1081/CRP-120023840.
11. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519–29. doi: 10.1056/NEJMra041842.
12. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008;27(41):5497–510. doi: 10.1038/onc.2008.245.
13. Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res. 2001;29(14):2905–19. doi: 10.1093/nar/29.14.2905.
14. Grimm SL, Hartig SM, Edwards DP. Progesterone receptor signaling mechanisms. J Mol Biol. 2016;428(19):3831–49. doi: 10.1016/j.jmb.2016.06.020.
15. Chaudhary AK, Ahmad S, Mazumder A. Cedrus deodara (Roxb.) Loud.: a review on its ethnobotany, phytochemical and pharmacological profile. Pharmacogn J. 2011;3(23):12–7. doi: 10.5530/pj.2011.23.2.
16. Pollier J, Goossens A. Oleanolic acid. Phytochemistry. 2012;77:10–5. doi: 10.1016/j.phytochem.2011.12.022.
17. Balázs Z, Nashev LG, Chandsawangbhuwana C, Baker ME, Odermatt A. Hexose-6-phosphate dehydrogenase modulates the effect of inhibitors and alternative substrates of 11β-hydroxysteroid dehydrogenase 1. Mol Cell Endocrinol. 2009;301(1–2):117–22. doi: 10.1016/j.mce.2008.10.021.
18. Goad DW, Bressy C, Holbrook MC, Grdzelishvili VZ. Acquired chemoresistance can lead to increased resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus. Mol Ther Oncolytics. 2022;24:59–76. doi: 10.1016/j.omto.2021.11.019.
19. Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA. 1969;208(9):1680–5. doi: 10.1001/jama.208.9.1680.

Regular Issue Subscription Original Research
Volume 01
Issue 01
Received 02/03/2023
Accepted 18/04/2023
Published 30/04/2023
Publication Time 59 Days
932

Login


My IP

PlumX Metrics